Postoperative atrial fibrillation (POAF) is the most common complication after cardiac surgery; it is reported in 10% to 65% of cases, depending
To test the theory that perioperative colchicine can prevent postpericardiotomy syndrome, these investigators randomized 360 patients undergoing
Postoperative atrial fibrillation (POAF) is the most common complication after cardiothoracic surgery or cardiac intervention
Patients were randomly assigned to colchicine or placebo groups starting 72 h before scheduled cardiac surgery and for 5 days thereafter (0
A short perioperative course of low-dose colchicine was effective to attenuate the postoperative biomarkers of myocardial injury and inflammation, and to decrease the
The most expensive self contain (single rooms) costs ₦38,000,000 per annum while the
Obio-Akpor has its headquarters at Rumuodomaya and is inhabited by the Igbo subgroup Ikwerre
Colchicine for Prevention of Post-Cardiac Surgery and Post-Pulmonary Vein Isolation Atrial Fibrillation: A Meta-Analysis November 2022 Reviews in Cardiovascular Medicine 23(12):387 Previous colchicine studies suggested rapid onset of action, 20 and that pretreatment for 2–3 days before cardiac surgery was not more effective in preventing perioperative atrial fibrillation and postpericardiotomy syndrome compared with initiating colchicine after cardiac surgery, 7, 21 supporting the decision to initiate study
The Colchicine for the Prevention of Perioperative Atrial Fibrillation (COP-AF) was an investigator-initiated, randomized, double-blind, placebo-controlled trial aiming to test the efficacy of low-dose colchicine in reducing the occurrence of clinically important perioperative atrial fibrillation (AF) and myocardial injury after major non-cardiac
It peaks at the end of the first post-operative week and usually decreases spontaneously
a randomized multicenter trial in which the prophylactic use of colchicine (initiated on Especially, the publications with the study codes 09 and 10 failed to show significant benefit of colchicine in patients after heart surgery (Fig
5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo
As a classical anti-inflammatory drug, colchicine may prevent the occurrence of PCP-AF
Postpericardiotomy syndrome (PPS) is a well-known complication after cardiac surgery
The
The first RCT was published by Imazio et al 10 in 2011 (“Colchicine reduces postoperative atrial fibrillation: results
We aim to evaluate the effect of colchicine on myocardial protection in patients who underwent non-CABG cardiac surgery
Pericardial effusion represents a common postoperative complication in cardiac surgery
Adler and coworkers 10 reported on 8 patients with recurrent pericarditis (5 idiopathic, 2 post–open heart surgery, 1 post chest trauma) who had not responded to NSAIDs (6 patients), corticosteroids (7 patients), and pericardiocentesis (3 patients)
This meta-analysis of 12 randomized controlled trials (RCTs) analyzed the feasibility and
40 Colchicine should be considered for PPS treatment according to ESC guidelines (class IIa recommendation, level of evidence B) using the pericarditis treatment regimens
Due to its efficacy in the prevention of the post-pericardiotomy syndrome, several small trials have investigated the use of colchicine for the prevention of postoperative AF